8.30am - 5.30pm EDT | 5.30am - 2.30pm PDT

8:30 am Opening Registration & Coffee Networking

8:50 am Chair’s Opening Remarks

Navigating the Landscape of Successful mRNA-Based Vaccines to Treat Infectious Disease

9:00 am Learnings from the Speedy Development of an mRNA-Based COVID-19 Vaccine

  • Andreas Kuhn Senior Vice President RNA Biochemistry & Manufacturing, BioNTech GmbH

Synopsis

  • Discussing the viability of mRNA as an effective therapeutic modality
  • Sharing insights of mRNA therapies to employ for future rapid development of vaccines against other infectious diseases and future pandemics
  • With a streamlined process from pre-clinical candidates through to large-scale production, what are the essential elements for future mRNA-based efforts

9:25 am Messenger RNA (mRNA) Vaccine Against Cytomegalovirus (CMV) Infection: Phase 2 Interim Data

  • Lori Panther Vice President, Clinical Development, Infectious Diseases, Moderna, Inc

Synopsis

  • A safe and effective vaccine against cytomegalovirus (CMV) infection remains a high priority in the effort to prevent congenital CMV
  • Interim data from a Phase 2, randomized, placebo-controlled, dosefinding trial assessing the safety and immunogenicity of candidate CMV vaccine mRNA-1647 will be presented
  • The interim data indicate that mRNA-1647 is well tolerated and immunogenic, supporting its ongoing development

9:50 am Pharmacology of Optimal mRNA Therapies for Infectious Disease Considering Safety, Efficacy & Translatability

  • Russell Johnson Local Head Basic Pharmaceutical Sciences, Drug Product, GSK Vaccines

Synopsis

  • Benchmarking between mRNA modalities for their effectivity, selectivity and translatability
  • Discussing conventional non-replicating vs self-amplifying mRNA’s therapies
  • Outlining data from animal models and comparing the utility for infectious disease

10:15 am From E. coli to mRNA Drug Substance – Development of Analytical and Purification Tools for a Scalable mRNA Production Process

  • Rok Sekirnik Head Process Development mRNA/ pDNA , BIA Separations

Synopsis

• mRNA purification platform from E. coli to mRNA DS will be presented,
including purification and linearization of pDNA, IVT reaction
optimization and a 2-step chromatogrpahy purification approach
• Development of a HPLC analytical to monitor IVT reaction kinetics,
including mRNA production and nucleotide/capping reagent
consumption, will be presented

10:40 am Live Panel Q&A – Ask Speakers your Burning Questions

  • Russell Johnson Local Head Basic Pharmaceutical Sciences, Drug Product, GSK Vaccines
  • Andreas Kuhn Senior Vice President RNA Biochemistry & Manufacturing, BioNTech GmbH
  • Lori Panther Vice President, Clinical Development, Infectious Diseases, Moderna, Inc
  • Venkata R Krishnamurthy Director & Senior Advisor, Eli Lilly & Company 
  • Rok Sekirnik Head Process Development mRNA/ pDNA , BIA Separations

11:00 am Morning Break & Speed Networking

12:00 pm LUNAR®-COV19: The Arcturus Therapeutics SARS-CoV-2 mRNA Vaccine Candidate

Synopsis

  • Overview of Arcturus Therapeutics Inc. self-replicating, messenger RNA based coronavirus (COVID-19) vaccine utilizing our STARR Technology™ platform
  • This vaccine platform combines a self-replicating RNA vector with LUNAR®, a leading nanoparticle non-viral delivery system, that together enable rapid manufacture, superior immune responses, and sustained protein expression
  • Replicating mRNA vaccines have several advantages over other vaccines, including higher expression, direct cytoplasmic activity, no possibility of genomic integration, and an inherent adjuvant effect through TLR activation

12:25 pm mRNA Therapeutics for Infectious Diseases: The CRISPR-Cas13 Way

  • Pooja Tiwari Associate Scientist, Emory School of Medicine  

Synopsis

  • Focussing on the applications of mRNA against infectious diseases
  • Discussing the ways of delivering therapeutic mRNA, especially to mucosal tissues
  • Elaborating on the applications of mRNA powered CRISPR-Cas13

12:50 pm Novel Delivery Appriaches to Enhance Stability, Effectivity & Safety of mRNA Therapies

  • Yizhou Dong Associate Professor, The Ohio State University 

Synopsis

  • Discussing key hurdles for mRNA delivery, from choosing the active ingredient through to the optimal route of delivery
  • Reviewing an effective delivery method to ensure vaccine safety, effectivity, potency, and tolerability
  • Overview of clinical and pre-clinical insights from effective approaches to mRNA vaccine delivery

1:15 pm Live Panel Q&A – Ask Speakers your Burning Questions

1:30 pm Networking Lunch

Exploring Translation & Optimal Development of mRNA Treatments for Oncology

2:30 pm Overview of Current Successes & Landscape of Clinical Data for mRNA Oncology Treatments

  • Tasuku Kitada Co-Founder, Director, President, & Head of R&D, Strand Therapeutics

Synopsis

  • Outlining current clinical and preclinical data indicating efficacy of mRNA cancer treatments
  • Reviewing the data which assesses the safety, tolerability, and immunogenicity

2:55 pm Targeting Cancer Using Artificial mRNA Treatments

Synopsis

  • Decoding mRNA translatability and stability from the 5’UTR
  • Lysosomal signalling pathways control ferroptosis of cancer cells
  • Targeting cancer using mRNA therapeutics

3:20 pm Live Panel Q&A – Ask Speakers your Burning Questions!

3:30 pm Afternoon Break & Poster Session – Present, Learn & Collaborate

Synopsis

As the success of mRNA therapies continue to grow and make significant impact for infectious disease and oncology around the globe, it is more important than ever to collaborate and learn with your peers as we continue to advance mRNA-based therapies through discovery and development. Join our dedicated session to share your latest data and have a first look about what your peers are working on!

4:00 pm Exquisitely Specific Anti-KRAS Biodegraders – Informing Cellular Prevalence of Nucleotide-Loaded States

Synopsis

  • Discussing how biodegrader established KRAS as a degradable protein
  • Exploring the utility of biodegraders, engineered with exquisite specificity
  • How combining mRNA transfection with a real-time degradation assay results in a high-throughput workflow for biodegrader evolution
  • Understanding how biodegraders that exclusively target the GDP loaded state inform on the cellular prevalence of nucleotide loaded states across various KRAS mutants

4:25 pm Insights from the Development of a Personalized mRNA Vaccine for Gastrointestinal Cancer Patients

  • Gal Cafri Immunotherapy & Genetic Engineering Group Leader, Sheba Medical Center

Synopsis

  • Insights from the pre-clinical development of a personalized mRNA vaccine for cancer patients
  • Clinical data from a phase I clinical trial using personalized mRNA vaccine targeting somatic and shared neoantigens
  • Thoughts regarding the future of mRNA technologies and vaccines in oncology

4:50 pm Live Panel Q&A – Ask Speakers your Burning Questions

5:00 pm Chair’s Closing Remarks

5:00 pm End of Conference Day One